FierceBiotech

Roche reports second positive study of RoACTEMRA given by subcutaneous injection to patients with rheumatoid arthritis

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the BREVACTA study of RoACTEMRA (tocilizumab, known as ACTEMRA outside Europe) given as a subcutaneous (SC) injection to patients with ...
FiercePharma

Roche receives EU approval for new subcutaneous formulation of RoACTEMRA providing more treatment flexibility for patients with moderate to severe rheumatoid arthritis

Roche receives EU approval for new subcutaneous formulation of RoACTEMRA providing more treatment flexibility for patients with moderate to severe rheumatoid arthritis First anti IL-6 receptor ...
PharmaTimes

CHMP nod for Roche’s subcutaneous RoActemra

Patients with rheumatoid arthritis (RA) in Europe are a giant step closer to receiving access to a subcutaneous formulation of Roche/Chugai's RoActemra, following the thumbs up from the European ...
Nasdaq

Roche: FDA Approves Actemra/RoActemra For Systemic Sclerosis-associated Interstitial Lung Disease

(RTTNews) - Roche (RHHBY) said FDA has approved Actemra/RoActemra subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated ...
Nasdaq

Roche’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis ...

Systemic sclerosis (SSc) is a rare disease that affects about 2.5 million people worldwide Approximately 80% of SSc patients may be affected by interstitial lung disease (ILD), a progressive disease ...